Cochrane reviews are structured, systematic, focused reviews of evidence in the field of medicine that either support or do not support specific forms of diagnosis and management of patients with or suspected of having particular disorders. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracy, biopsy, Diagnosis, fusion, MRI, MRi-guided, MRI/TRUS, prognosis, scan | 3 Comments »
Many prostate cancer patients — and particularly those who don’t like the idea of prostate biopsies — think that if one uses MRI-guided biopsies alone one might only need to have one or two biopsy cores taken to accurately diagnose prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, cores, fusion, MRI, MRI/TRUS, number, scan | 7 Comments »
A recent report in Urology Practice makes what we see as a somewhat odd statement about what patients may be willing to pay for an MRI/TRUS fusion-guided biopsy as opposed to a TRUS-guided prostate biopsy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: biopsy, cost, fusion, MRI | 4 Comments »
A new article in the Journal of Urology has provided us with some initial insight into the value of multiparametric MRIs (mpMRIs) in monitoring progression of patients on active surveillance protocols. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, biopsy, fusion, mpMRI, MRI, MRI/TRUS, multiparametric, surveillance | 1 Comment »
An important article by Siddiqui et al. appears in this week’s issue of the Journal of the American Medical Association. It deals with the experience of Dr. Peter Pinto and his colleagues in the diagnosis of prostate cancer in about 1,000 patients over the past few years. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, fusion, MRI, MRI/TRUS, standard, systematic | Leave a comment »
A new study just reported in the Journal of Urology provides information on the application of MRI/TRUS fusion-guided prostate biopsy to diagnose prostate cancer in a community-like urology practice (as opposed to a major prostate cancer research center). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, fusion, MRI/TRUS, risk | Leave a comment »
The first issue of the new journal Urology Practice includes a very nice review of the use of MRI imaging in the evaluation, diagnosis, and biopsy of men with prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, fusion, MRI, multiparametric, risk | Leave a comment »
A recent video-discussion on the OncLive web site addresses the complexities in the evolution of application of multiparametric MRI scanning and MRI/TRUS fusion biopsies in the diagnosis of early stage prostate cancers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, fusion, MRI, multiparametric, TRUS | 2 Comments »
Readers interested on a the potential future of office-based prostate cancer imaging (for the conduct of biopsies and perhaps for other purposes too) may be interested in an article published today on the HealthDay web site. … READ MORE …
Filed under: Diagnosis, Management, Risk, Uncategorized | Tagged: biopsy, fusion, MRI, offic e-based, TRUS | 2 Comments »
A newly published paper by the prostate cancer clinical research group at the National Cancer Institute (NCI) in Bethesda, Maryland, has reported on the use of magnetic resonance-ultrasound (MRI-US)-guided fusion biopsies, with specific emphasis on its value in men with larger prostates (i.e., prostates > 40 cm3 in volume). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, fusion, MRI-US, risk | Leave a comment »
A Phase II clinical trial being coordinated by researchers at the University of Michigan Cancer Center is (as far as we know) the first trial ever to explore the potential of treatment for men with metastatic, castration-resistant prostate cancer (mCRPC) who carry the TMPRSS2-EPG fusion gene (as opposed to those who do not). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ABT-888, fusion, gene, inhibitor, PARP, TMPSS2-ERG, veliparib | 2 Comments »
A new paper in this month’s Journal of Urology has suggested that biopsy of lesions identified using a 3.0 T MRI scan and targeted for biopsy using an MRI/ultrasound image fusion technique may be able to significantly improve the probability of detection of clinically relevant prostate cancers in an office setting. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: biopsy, Diagnosis, fusion, MRI, ultrasound | 8 Comments »
A new paper by a multi-center research team has refined the long-held suspicion that some types of aggressive prostate cancer may be the consequence of the accumulation of multiple mutations in the patients’ DNA. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, fusion, gene, risk | Leave a comment »
According to a media release from the Prostate Cancer Foundation yesterday, research at the University of Michigan Comprehensive Cancer Center suggests that the RAF oncogene that drives fatal forms of melanoma (an aggressive type of skin cancer) may also drive aggressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Risk, Uncategorized | Tagged: fusion, gene, oncogene, RAF | 5 Comments »
An article in today’s Israel Herald might give you the (incorrect) idea that androgen deprivation therapy is completely inappropriate as a form of treatment for prostate cancer. … READ M\ORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: development, fusion, gene | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 